UBS Asset Management Americas Inc. grew its stake in Taro Pharmaceutical Industries Ltd. (NYSE:TARO) by 0.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 19,296 shares of the company’s stock after buying an additional 39 shares during the quarter. UBS Asset Management Americas Inc.’s holdings in Taro Pharmaceutical Industries were worth $2,162,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently modified their holdings of the business. Fort L.P. increased its position in Taro Pharmaceutical Industries by 2.1% in the second quarter. Fort L.P. now owns 179,005 shares of the company’s stock worth $20,059,000 after buying an additional 3,748 shares in the last quarter. Freestone Capital Holdings LLC increased its position in Taro Pharmaceutical Industries by 0.3% in the second quarter. Freestone Capital Holdings LLC now owns 142,750 shares of the company’s stock worth $15,996,000 after buying an additional 441 shares in the last quarter. River Road Asset Management LLC increased its position in Taro Pharmaceutical Industries by 33.3% in the second quarter. River Road Asset Management LLC now owns 65,470 shares of the company’s stock worth $7,337,000 after buying an additional 16,350 shares in the last quarter. NN Investment Partners Holdings N.V. increased its position in Taro Pharmaceutical Industries by 2.0% in the second quarter. NN Investment Partners Holdings N.V. now owns 53,976 shares of the company’s stock worth $6,049,000 after buying an additional 1,064 shares in the last quarter. Finally, Aperio Group LLC increased its position in Taro Pharmaceutical Industries by 46.9% in the second quarter. Aperio Group LLC now owns 50,826 shares of the company’s stock worth $5,696,000 after buying an additional 16,233 shares in the last quarter. Institutional investors and hedge funds own 14.20% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: “UBS Asset Management Americas Inc. Boosts Position in Taro Pharmaceutical Industries Ltd. (TARO)” was originally published by Watch List News and is owned by of Watch List News. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States and international trademark and copyright legislation. The correct version of this report can be viewed at https://www.watchlistnews.com/ubs-asset-management-americas-inc-boosts-position-in-taro-pharmaceutical-industries-ltd-taro/1633974.html.

Shares of Taro Pharmaceutical Industries Ltd. (NYSE TARO) opened at 110.47 on Monday. The firm has a 50-day moving average price of $108.31 and a 200-day moving average price of $111.13. Taro Pharmaceutical Industries Ltd. has a 12 month low of $92.28 and a 12 month high of $124.52. The stock has a market cap of $4.47 billion, a PE ratio of 11.25 and a beta of 0.65.

A number of brokerages have commented on TARO. TheStreet upgraded Taro Pharmaceutical Industries from a “c” rating to a “b-” rating in a research report on Thursday, July 20th. BidaskClub cut Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research report on Thursday.

Taro Pharmaceutical Industries Company Profile

Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.

Want to see what other hedge funds are holding TARO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Taro Pharmaceutical Industries Ltd. (NYSE:TARO).

Institutional Ownership by Quarter for Taro Pharmaceutical Industries (NYSE:TARO)

Receive News & Ratings for Taro Pharmaceutical Industries Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries Ltd. and related companies with Analyst Ratings Network's FREE daily email newsletter.